Selpercatinib｜Thyroid Cancer｜HongKong DengYue Medicine

Selpercatinib Application Scope

Selpercatinib is a highly selective RET (Rearranged during Transfection) kinase inhibitor used for the treatment of the following conditions:

1. Non-Small Cell Lung Cancer (NSCLC): For patients with advanced or metastatic NSCLC harboring RET gene fusions.
2. Thyroid Cancer:
   • For patients with advanced or metastatic medullary thyroid cancer (MTC) harboring RET gene fusions.
   • For patients with advanced or metastatic thyroid cancer harboring RET gene mutations.
3. Other Solid Tumors: For patients with advanced or metastatic solid tumors harboring RET gene alterations.

Selpercatinib Characteristics

Ingredients:

• Active ingredient: Selpercatinib
• Excipients: May include microcrystalline cellulose, lactose, magnesium stearate, etc., depending on the formulation.

Properties:

• Appearance: Typically tablets or capsules.
• Color: May be white or light-colored, depending on the dosage form.

Specification:

• Dosage per tablet/capsule: Common specifications include 40 mg or 80 mg.

Packaging Specification:

• Each box typically contains 30 or 60 tablets.

Storage:

• Storage temperature: 20°C to 25°C (68°F to 77°F).
• Protect from light and moisture, and keep in the original packaging.

Expiry Date:

• Refer to the expiration date on the packaging; do not use if expired.

Executive Standard:

• Complies with relevant standards from the FDA (U.S. Food and Drug Administration) or NMPA (China National Medical Products Administration).

Approval Number:

• Refer to the approval number on the packaging.

Date of Revision:

• Refer to the latest revision date on the drug leaflet.

Manufacturer:

• Eli Lilly and Company or its authorized manufacturers.

Guidelines For The Use Of Selpercatinib

Dosage and Administration:

• Recommended dose: 160 mg twice daily (taken on an empty stomach or with food).
• Swallow the tablet whole; do not crush, chew, or split.
• If a dose is missed, take the next dose at the regular time; do not double the dose.

Adverse Reactions:
Common adverse reactions include:

• Liver function abnormalities (e.g., elevated ALT/AST)
• Hypertension
• Diarrhea
• Fatigue
• Nausea
• Constipation
• Edema
• Rash

If severe adverse reactions occur (e.g., hepatotoxicity, QT prolongation), discontinue use immediately and seek medical attention.

Contraindications:

• Hypersensitivity to Selpercatinib or any excipients.

Precautions:

• Regularly monitor liver function, blood pressure, and electrocardiogram (QT interval) during treatment.
• Pregnant or breastfeeding women should use under medical supervision.
• Safety and efficacy in pediatric patients have not been established.

 Interactions

Drug Interactions:

• Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): May increase Selpercatinib plasma concentrations; use with caution.
• Strong CYP3A inducers (e.g., rifampin, phenytoin): May decrease Selpercatinib plasma concentrations; dose adjustment may be required.
• Proton pump inhibitors (PPIs): May reduce Selpercatinib absorption; consider staggered administration.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.